Integrated Genetics Lab Services Conducting COVID-19 Testing in Spain Utilizing Fluidigm Biomark HD Platform
24 June 2020 - 10:30PM
Fluidigm Corporation (Nasdaq:FLDM), an innovative
biotechnology tools provider with a vision to improve life through
comprehensive health insight, today announced that Integrated
Genetics Lab Services (iGLS), a leading provider of advanced
and integrated genetic services for reproductive medicine, is among
the companies chosen by Spanish health authorities to expand
SARS-CoV-2 screening in the Spanish population. iGLS is
utilizing Fluidigm® microfluidics technology and reagents
in a COVID-19 testing workflow designed to be run on
the Fluidigm Biomark™ HD system.
The nasopharyngeal swab-based COVID-19 test is intended to
increase testing capacity for patients, health care workers and
employee populations across Spain. iGLS received a grant from the
local Valencian government to support its testing program and began
screening in early June.
“Supporting our first responders in Spain and their patients as
well as organizations and employers with COVID-19 testing are the
goals of our program,” said Dr. Jon Aizpurua, MD, PhD, President
and CEO of iGLS. “While the rate of infection has moderated in
Spain, scalable, cost-effective and accurate testing is more
critical than ever. The Fluidigm integrated fluidic circuit
technology, reagents and workflow are ideally suited to this
task.”
COVID-19 testing on the Fluidigm Biomark HD provides throughput
and cost advantages that reduce the impact of capacity‑constrained
supply chains. The company’s microfluidics technology enables
processing of more samples per batch and uses a fraction of
expensive testing reagents per sample as compared to more
traditional, microwell plate-based PCR technology.
“Labs in many part of the world are seeing the unique value
proposition of Fluidigm technology to provide testing
infrastructure that offers speed, scale and automation,” said Chris
Linthwaite, President and CEO of Fluidigm. “In addition to growing
adoption of our technology for COVID-19 testing in the United
States, labs in other regions of the globe are utilizing Fluidigm
microfluidics for ultrahigh-throughput screening, which is
particularly relevant in countries with high infection rates.
“Fluidigm supports multiple approaches to COVID-19 testing,
having recently filed for Emergency Use Authorization from the U.S.
Food and Drug Administration for an extraction-free saliva-based
test to detect COVID-19,” Linthwaite said. “Getting the global
economy back to work will require testing on a major scale. The
capacity of a single Biomark HD system supports up to 6,000 tests
per day and more than 2 million annual tests.
“We are honored to have been chosen by iGLS to increase
critically needed COVID-19 testing capacity in Spain.”
About Fluidigm Fluidigm (Nasdaq:FLDM)
focuses on the most pressing needs in translational and clinical
research, including cancer, immunology, and immunotherapy. Using
proprietary CyTOF® and microfluidics technologies, we develop,
manufacture, and market multi-omic solutions to drive meaningful
insights in health and disease, identify biomarkers to inform
decisions, and accelerate the development of more effective
therapies. Our customers are leading academic, government,
pharmaceutical, biotechnology, and plant and animal research
laboratories worldwide. Together with them, we strive to increase
the quality of life for all. For more information,
visit fluidigm.com. Fluidigm, the Fluidigm logo,
Biomark, and CyTOF are trademarks and/or registered trademarks
of Fluidigm Corporation in the United
States and/or other countries. All other trademarks are the
sole property of their respective owners. Fluidigm products are
provided for Research Use Only. Not for use in diagnostic
procedures.
Available Information We use our website
(fluidigm.com), investor site (investors.fluidigm.com), corporate
Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm),
and LinkedIn page (linkedin.com/company/fluidigm-corporation) as
channels of distribution of information about our products, our
planned financial and other announcements, our attendance at
upcoming investor and industry conferences, and other matters. Such
information may be deemed material information, and we may use
these channels to comply with our disclosure obligations under
Regulation FD. Therefore, investors should monitor our website and
our social media accounts in addition to following our press
releases, SEC filings, public conference calls, and
webcasts.
Forward-Looking Statements for Fluidigm This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, among others, statements regarding the adoption of
Fluidigm microfluidics technology for COVID-19 testing and its
anticipated benefits. Forward-looking statements are subject to
numerous risks and uncertainties that could cause actual results to
differ materially from currently anticipated results, including but
not limited to risks relating to the potential adverse effects of
the coronavirus pandemic on our business and operating results
during 2020; our ability and/or the ability of the research
institutions utilizing our products and technology to obtain EUA
FDA and any other requisite approvals to use our products and
technology for diagnostic testing purposes; challenges inherent in
developing, manufacturing, launching, marketing, and selling new
products; risks relating to company research and development and
distribution plans and capabilities; interruptions or delays in the
supply of components or materials for, or manufacturing of,
Fluidigm products; potential product performance and quality
issues; intellectual property risks; and competition. Information
on these and additional risks and uncertainties and other
information affecting Fluidigm business and operating results is
contained in Fluidigm’s Annual Report on Form 10-K for the year
ended December 31, 2019, and in its other filings with the
Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof. Fluidigm disclaims any
obligation to update these forward-looking statements except as may
be required by law.
Media: Mark Spearman Senior Director, Corporate
Communications 650 243 6621mark.spearman@fluidigm.com
Investors: Agnes Lee Vice President, Investor
Relations 650 416 7423 agnes.lee@fluidigm.com
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Apr 2024 to May 2024
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From May 2023 to May 2024